Jim Cramer Notes McKesson (MCK) Reported "Very Strong Set of Numbers"

We recently published a list of 8 Stocks on Jim Cramer’s Radar Recently. In this article, we are going to take a look at where McKesson Corporation (NYSE:MCK) stands against other stocks that Jim Cramer discussed recently.

On Wednesday’s episode of Mad Money, Jim Cramer reviewed the recent developments affecting drug distribution companies and laid out why he is turning cautious on the group. He pointed out that stocks of major drug distributors have retreated from their all-time highs.

“Most of the time, that’s because of vague, amorphous concerns that some type of regulatory crackdown will force them out of business or, at the very least, make them a lot less profitable.”

READ ALSO Jim Cramer Put These 8 Stocks Under a Microscope Recently and Jim Cramer Commented on These 6 Natural Gas Players

Cramer referenced the executive order signed by the President last week aimed at lowering drug prices, which triggered a sell-off across the drug distribution sector. He explained that the order would effectively require pharmaceutical companies to offer the U.S. government drug prices that match the lowest rates charged in other advanced economies. Cramer said the market’s fear is straightforward: if drugmakers are forced to cut prices for their government customers, then drug distributors could see their margins shrink.

“The bottom line: No matter how well the drug distributors have been doing, I do not want to stick my neck out for an industry that now seems to be hated by both the Democrats and the Republicans. It seems like the only thing they agree on, doesn’t it? There are so many potential winners in this market, I say, why take the risk?”

Our Methodology

For this article, we compiled a list of 8 stocks that were discussed by Jim Cramer during the episodes of Mad Money aired on May 14. We listed the stocks in the order that Cramer mentioned them. We also provided hedge fund sentiment for each stock as of the fourth quarter of 2024, which was taken from Insider Monkey’s database of over 1,000 hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

McKesson Corporation (NYSE:MCK)

Number of Hedge Fund Holders: 78

McKesson Corporation (NYSE:MCK) was mentioned during the episode, and here’s what Mad Money’s host had to say:

“These stocks, namely Cardinal Health, Cencora, and McKesson, are seemingly perpetual residents on the new high list. Over the long haul, they’re some of the best performers out there, and they’ve done great this year, as is pretty much always the case. And yet, doesn’t it always feel like the drug distributors are just one bad day away from falling apart… The last quarter from the major drug distributors came from McKesson, and that was last Thursday night, which delivered yet another very strong set of numbers… Like the others. McKesson had a top-line miss, in this case, actually a pretty sizable one, but still delivered a significant earnings beat, and gave a higher-than-expected full-year earnings forecast in a vacuum.

I think the McKesson quarter was strong enough to spark a nice rally for the stock last Friday. But we don’t live in a vacuum, do we?… The big negative development for the drug distributors came midweek when Politico reported that President Trump would be reviving an effort to dramatically cut drug costs by adopting what’s known as the Most-Favored-Nation pricing for Medicare…

As a result, all the drug distributors are either flat or slightly lower this week… so that’s the conundrum with these middlemen, Cardinal, Cencora, and McKesson are all doing incredibly well, but like I said before, there always seems to be a threat that they could be regulated out of existence.”

McKesson (NYSE:MCK) provides healthcare services by distributing medications, medical products, and handling logistics. The company also supplies technology tools, advisory services, and support for healthcare providers, biopharma companies, and patients.

Overall, MCK ranks 6th on our list of stocks that Jim Cramer discussed recently. While we acknowledge the potential of MCK as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than MCK but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.